Your browser doesn't support javascript.
Immunotherapy of multisystem inflammatory syndrome in children (MIS-C) following COVID-19 through mesenchymal stem cells.
Suksatan, Wanich; Chupradit, Supat; Yumashev, Alexei Valerievich; Ravali, Sahithya; Shalaby, Mohammed Nader; Mustafa, Yasser Fakri; Kurochkin, Anatoley; Siahmansouri, Homayoon.
  • Suksatan W; Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand.
  • Chupradit S; Department of Occupational Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
  • Yumashev AV; Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russia.
  • Ravali S; Department of Pharmacy Practice, SRM College of Pharmacy, SRM Institute of Science and Technology, Chennai, India.
  • Shalaby MN; Faculty of Physical Education, Suez Canal University, Egypt.
  • Mustafa YF; Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul 41001, Iraq.
  • Kurochkin A; Kazan Federal University, Russia.
  • Siahmansouri H; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: Homayoon_siyahmansoori@yahoo.com.
Int Immunopharmacol ; 101(Pt B): 108217, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1446737
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new type of coronavirus causing coronavirus 2019 (COVID-19) that was first observed in Wuhan, China, in Dec. 2019. An inflammatory immune response targeting children appeared during the pandemic, which was associated with COVID-19 named multisystem inflammatory syndrome in children (MIS-C). Characteristics of MIS-C include the classic inflammation findings, multi-organ dysfunction, and fever as the cardinal feature. Up to now, no specific therapy has been identified for MIS-C. Currently, considerable progress has been obtained in the MIS-C treatment by cell therapy, specially Mesenchymal stem cells (MSCs). Unique properties have been reported for MSCs, such as various resources for purification of cell, high proliferation, self-renewal, non-invasive procedure, tissue regenerator, multidirectional differentiation, and immunosuppression. As indicated by a recent clinical research, MSCs have the ability of reducing disease inflammation and severity in children with MIS-C. In the present review study, the benefits and characteristics of MSCs and exosomes are discussed for treating patients with MIS-C.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Systemic Inflammatory Response Syndrome / Mesenchymal Stem Cell Transplantation / COVID-19 / Immunotherapy Type of study: Prognostic study Topics: Long Covid Limits: Animals / Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108217

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Systemic Inflammatory Response Syndrome / Mesenchymal Stem Cell Transplantation / COVID-19 / Immunotherapy Type of study: Prognostic study Topics: Long Covid Limits: Animals / Humans Language: English Journal: Int Immunopharmacol Journal subject: Allergy and Immunology / Pharmacology Year: 2021 Document Type: Article Affiliation country: J.intimp.2021.108217